Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.
Follow ZVRA
Zevra Therapeutics, Inc. (ZVRA) Dividend Safety Score
Zevra Therapeutics, Inc.'s Dividend Safety Score for fiscal 2025 cannot be worked out: does not pay a regular dividend.
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings | 0.00% | — | Pass | 25 |
| Payout of free cash flow free cash flow at or below zero | — | — | Fail | 0 |
| Net debt / EBITDA net cash | — | — | Pass | 20 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 10 fiscal years | 9 | — | Fail | 0 |
| Dividend Safety Score | n/a — does not pay a regular dividend | — | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| CLYM Climb Bio, Inc. compare | — |
| ZVRA Zevra Therapeutics, Inc. | — |
| OLMA Olema Pharmaceuticals, Inc. compare | — |
| PHAT Phathom Pharmaceuticals, Inc. compare | — |
| SLDB Solid Biosciences Inc. compare | — |
| NVCT Nuvectis Pharma, Inc. compare | — |
| SLN Silence Therapeutics PLC Sponsored ADR compare | — |
| WVE WAVE Life Sciences Ltd. compare | — |
| CRMD CorMedix Inc compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings